Toyama, Kaoru
Furuie, Hidetoshi
Kuroda, Kana
Ishizuka, Tomoko
Okuda, Yasuyuki
Shimizu, Takako
Kato, Manabu
Igawa, Yoshiyuki
Nishikawa, Yasuhiro
Ishizuka, Hitoshi
Funding for this research was provided by:
Daiichi-Sankyo
Article History
Accepted: 24 June 2021
First Online: 12 August 2021
Declarations
:
: This study was funded by Daiichi Sankyo Co., Ltd.
: KT, KK, TI, YO, TS, MK, YI, YN, and HI are employees of Daiichi Sankyo Co., Ltd. KK, TI, TS, YI, and HI own stocks in the company. HF has received research funding for this study from Daiichi Sankyo Co., Ltd.
: The study was conducted after review and approval by the institutional review board of Osaka Pharmacology Clinical Research Hospital, Osaka, Japan (control number of the study site 930PC). The study was conducted in accordance with Good Clinical Practice and ethical principles of the Declaration of Helsinki and the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act.
: All subjects provided written informed consent to be included in the study (JapicCTI No. 152832).
: KK, TI, and YO performed all statistical analyses. KT drafted the manuscript. HF conducted the study and collected the data. All authors contributed to the design and implementation of the research and provided critical feedback on the manuscript. All authors approved the final manuscript before submission.
: All de-identified patient data relevant to this study are included in this article. Additional data and supporting documents pertaining to this study are provided upon reasonable request made via this web address (ExternalRef removed) in accordance with the data sharing policy of Daiichi Sankyo Co., Ltd.
: Not applicable.
: Not applicable.